Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 12Brain Neoplasms 6Breast Neoplasms, Male 5Glioblastoma 4Gliosarcoma 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Salivary Gland Neoplasms 2Prostatic Neoplasms 2Oligodendroglioma 2Glioma 2Gallbladder Neoplasms 2Ependymoma 2Carcinoma, Hepatocellular 2Bile Duct Neoplasms 2Astrocytoma 2Tongue Neoplasms 1Thyroid Neoplasms 1Thymoma 1Spinal Cord Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Neoplasms 1Melanoma 1Medulloblastoma 1Insulin-Like Growth Factor I, Resistance To 1Familial ependymoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Central Nervous System Neoplasms 1

Interventions

Sunitinib 2Cyclophosphamide 2Celecoxib 2saracatinib 1fludarabine 1entinostat 1belinostat 1avelumab 1alovudine 1MK 2206 1Lapatinib 1FANG vaccine 1Erlotinib Hydrochloride 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Thymoma × Lapatinib × Clear all
NCT01306045 2024-10-01

Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
647 enrolled 17 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Thymoma, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡